Neovasc Inc. (NASDAQ:NVCN) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Hold” Signal.
Neovasc Inc. (NASDAQ:NVCN) gained 1.86 Percent and closed its previous trading session at $0.04. The stock traded with the average Volume of 64.58 Million at the end of last session.
Neovasc Inc. (NASDAQ:NVCN) has the Market Capitalization of 3.03 Million. The Stock has its 52-week High of $1.890 and 52-Week Low of $0.030 and it touched its 52-week high on 09/20/17 and 52-Week Low on 05/16/18
The company reported its last earnings Actual EPS of $-0.06/share. While, the analyst predicted that the company could provide an EPS of $-0.07/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 14.3 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Neovasc Inc. (NASDAQ:NVCN) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -0.53% where SMA50 and SMA200 are 0.78% and -92.46% respectively.
Neovasc Inc. (NASDAQ:NVCN) currently has a Weekly Volatility of 8.12% percent while its Monthly Volatility is at 9.08% percent. While talking about Performance of the Stock, Neovasc Inc. currently has a Weekly performance of -8.57%, monthly performance percentage is 10.66 percent, Quarterly performance is -28.76 percent, 6 months performance shows a percent value of -92.63% and Yearly Performance is -97.18 percent.
Neovasc Inc. is a specialty medical device company. It develops, manufactures and markets products for the cardiovascular marketplace. The Company’s products include the Tiara (TM) mitral valve prosthesis in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer (TM) for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Neovasc Inc. is headquartered in Richmond, Canada.